Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Summary

Primary objective : * To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode. Secondary objectives: * To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.

Timeline

Start

2003-11

Primary completion

2004-05

Completion

2004-10

Drugs

Indications